Background: Glial cell-derived neurotrophic factor (GDNF) is a survival factor for
INTRODUCTION
Glial cell derived neurotrophic factor (GDNF) was initially described as a potent neurotrophic factor for dopaminergic neurons, regarded as a promising therapeutic agent for PD 1 . Several animal studies and a few clinical trials have set the requirements for proper GDNF treatment [2] [3] [4] . Intracerebroventricular injection of GDNF in PD patients caused severe side effects, without improving parkinsonian symptoms 5, 6 , probably because GDNF did not reach the target tissues 7 . For these reasons, GDNF
should be delivered locally to the caudate-putamen in humans or striatum in rodents 8 .
The results from two independent open-label trials showed that the sustained delivery of GDNF within the putamen using a mechanical pump reduced the motor symptoms and achieved a partial restoration of the nigrostriatal pathway 9, 10 . These promising results
were in contrast to the findings in the first double-blind placebo-controlled study in which GDNF infusion, at a lower dose and using a wider catheter, failed to improve motor symptoms in patients 11 . The lack of efficacy in this trial, the appearance of antibodies against GDNF and cerebellar lesions in monkeys receiving very high doses of GDNF, resulted in the withdrawal of GDNF from all clinical tests. These studies concluded that a new delivery system should be developed before considering GDNF infusion in human patients. This has prompted researchers to seek alternative methods for long-term protein delivery.
In the present study we propose the use of biodegradable and biocompatible non-toxic poly-lactic-co-glycolic acid (PLGA) microspheres for sustained GDNF delivery into the brain. The goal of this work was to asses whether a single low dose of microencapsulated GDNF would be sufficient to maintain long-term beneficial neuroestorative and/or neuroprotective effect in the partial 6-hydroxydopamine (6-OHDA) rat model of PD. We provide evidence that encapsulated GDNF may be 5 delivered to the striatum, inducing a long-lasting recovery of lesion-induced motor impairment. Restoration of functional behavior is accompanied by striatal dopaminergic fiber sprouting, neuroprotection of dopaminergic cells at the SNpc level and an increase in tyrosine hydroxylase phosphorylation.
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MATERIAL AND METHODS
Microsphere preparation.
Rat recombinant glycosylated GDNF was expressed and purified as previously described 12 . GDNF-loaded microspheres were prepared using the solvent extraction/evaporation method utilizing TROMS technology 13 . Fluorescent microspheres were prepared similarly but encapsulating rhodamine B isothiocyanate (0.1 mg) in the inner aqueous phase instead of GDNF.
Animal procedures.
Animals. Female Sprague-Dawley rats of 220-240 g were obtained from Harlan Histological techniques and optic density measurements were performed as described previously 15 .
Statistical analysis
Those data following a normal distribution were analyzed using independent Student´s t test and non-parametric data using a Wilcoxon test for independent samples. A p value < 0.05 was considered significant.
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RESULTS
Assessment of biodegradability of PLGA microspheres in vivo
We first evaluated whether GDNF-microspheres were present 28 weeks after their implantation. Microspheres loaded with rhodamine were prepared and injected within the rat striatal parenchyma. Animals were sacrificed at different times and rhodaminemicrospheres were visualized by confocal microscopy (Fig. 1A) . Between the first and second week there was a large decrease in the microsphere injection size that continued to decrease, at a lower rate, over time. Importantly, a significant amount of microspheres were still detectable at week 28th post-injection.
Microencapsulated GDNF reverses altered motor behavior in a PD animal model
To evaluate the long-term effect of encapsulated GDNF the partial 6-OHDA animal model was used. The extent of the lesion was assessed 13 days after the toxic 
Effect of GDNF-microsphere treatment on TH-positive cells
The effect of GDNF-microspheres at the striatal level was evaluated by TH immunohistochemistry. Intrastriatal injections of GDNF-microspheres induced profuse TH-immunoreactive (TH-ir) fiber sprouting surrounding the injection areas (Fig. 1C) . In contrast, only the injection tract was visible around the injection sites of empty microspheres. Aberrant sprouting in the globus pallidus was not observed 16 .
Densitometric analysis at three different striatal rostrocaudal levels (Fig. 1D) showed a 9 22% increase in the area of TH immunoreactivity at the most caudal striatal levels. Our results suggest that these fibers are likely to arise from sprouting by the remaining terminals located within the ventral striatum and the nucleus accumbens.
TH-ir neurons were counted in three sections throughout the central portion of the SNpc, at the level of the medial terminal nucleus of the accessory optic tract (Fig. 2A) .
A statistically significant 1.7-fold increase in the number of TH-ir cells was observed within the SNpc of animals treated with GDNF-microspheres (Fig. 2B) . The degree of TH activity within these cells was studied by double immunofluorescence to detect the form of the enzyme TH phosphorylated at ser31 17, 18 (Fig. 2C ). All cells detected were double labeled and fluorescence signal corresponding to pTH with respect to THpositive cells was quantified. A significant increase in this ratio at the SNpc level was found in GDNF-treated animals (Fig. 2D ). This was not observed at the VTA level (Fig.   2E ). These results suggest that the improvement in behavior induced by GDNFmicrospheres could be due to both a neuroprotective effect on dopaminergic cells and an increase in TH activity.
DISCUSSION
The results of the present study demonstrate that PLGA microspheres are an efficient vehicle for sustained delivery of neurotrophic factors to the brain. Biodegradable and biocompatible PLGA microspheres offer an interesting alternative and have already been used in clinical practice for the treatment of human gliomas 19, 20 . Microspheres release drugs locally for an extended period of time, have a low risk of side effects and protect the encapsulated protein from degradation by tissue proteases.
Several studies to determine neuroprotection have been performed by administrating GDNF prior to performing the 6-OHDA lesion 16, [21] [22] [23] [24] . While these studies are interesting for testing the efficacy of GDNF, the administration of the trophic factor after a lesion would have greater clinical relevance. For this reason, GDNFmicrospheres were implanted intrastriatally 14 days after the 6-OHDA lesion. At 28 weeks post-implantation, microspheres were still present and the GDNF beneficial effect was preserved. GDNF was clearly detected by immunohistochemistry 5 weeks after microparticles implantation 15 . In the present study, the immunohistochemistry procedure failed to detect the presence of GDNF, probably because the remaining protein was under the detection threshold of the technique. It may be assumed that very low GDNF doses are enough to maintain the beneficial effect as previous studies have demonstrated that protein withdrawal in PD patients 25 or GDNF viral expression switch off, reversed GDNF effect 26 . The distribution of the trophic factor is another important issue. In this study, two intrastriatal microparticle injections were sufficient to promote a stable functional recovery of the 6-OHDA animal model. The number of microparticle injections may be increased for non-human primates or human brains with a larger putaminal volume.
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An additional issue with GDNF-based therapy is the production of neutralizing antibodies against GDNF 11 . An immune reaction against the E. coli unglycosylated recombinant protein used in the clinical trial could be responsible for the production of autoantibodies 27 . To overcome this potential problem, glycosylated recombinant rat GDNF was used in our study 12 and the absence of anti-GDNF antibodies was confirmed 15 .
The low dose required in the present approach to achieve a functional effect was also remarkable. A total amount of 2.5 µg of GDNF was sufficient for the long-term effect of GDNF treatment. Considering that the human putamen volume is 171 times larger than the rat striatum 28 29 , an estimation of the dose necessary for patients for a 28 week treatment would be 427 µg.
The main achievement of this study was the stable long-term functional recovery in parkinsonian animals induced by GDNF treatment initiated after the 6-OHDA lesion.
The results of this work indicate that microspheres should be considered as a method to deliver GDNF directly to the striatum for the treatment of PD.
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